Zydus, Lupin Partner to Co-Market Semaglutide in India.

: Expands presence in metabolic therapies via collaboration. : Strengthens diabetes portfolio and domestic reach. Zydus and Lupin have entered a co-marketing agreement to distribute semaglutide injections in India, a drug widely used for diabetes and weight management. The partnership aims to leverage both companies’ sales networks to improve market penetration. Such alliances help scale commercialization, improve therapy access, and enhance revenue visibility in high-growth chronic segments. Both companies are part of NIFTY 500; semaglutide demand is rising globally. Strategic collaborations can accelerate market access and strengthen therapeutic portfolios. Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice.